International Journal of Cancer Management

Published by: Kowsar
Crossmark

Downregulation of Plasma MiR-142-3p and MiR-26a-5p in Patients With Colorectal Carcinoma

Reza Ghanbari 1 , 2 , Neda Mosakhani 3 , Jahanbakhsh Asadi 4 , * , Nazila Nouraee 5 , Seyed Javad Mowla 5 , Yaghoub Yazdani 6 , Ashraf Mohamadkhani 2 , Hossein Poustchi 2 , Sakari Knuutila 3 and Reza Malekzadeh 2
Authors Information
1 Faculty of Advanced Medical Technologies, Golestan University of Medical Sciences, Gorgan, IR Iran
2 Digestive Oncology Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, IR Iran
3 Department of Pathology, Haartman Institute, Helsinki University, Helsinki, Finland
4 Metabolic Disorders Research Center, Golestan University of Medical Sciences, Gorgan, IR Iran
5 Department of Molecular Genetics, Faculty of Biological Sciences, Tarbiat Moddares University, Tehran, IR Iran
6 Infectious Disease Research Center, Golestan University of Medical Sciences, Gorgan, IR Iran
Article information
  • Iranian Journal of Cancer Prevention: May 28, 2015, 8 (3); e2329
  • Published Online: May 22, 2015
  • Article Type: Research Article
  • Received: October 21, 2014
  • Revised: November 5, 2014
  • Accepted: November 12, 2014
  • DOI: 10.17795/ijcp2329

How to Cite: Ghanbari R, Mosakhani N, Asadi J, Nouraee N, Mowla S J, et al. Downregulation of Plasma MiR-142-3p and MiR-26a-5p in Patients With Colorectal Carcinoma, Int J Cancer Manag. 2015 ; 8(3):e2329. doi: 10.17795/ijcp2329.

Abstract
Copyright © 2015, Iranian Journal of Cancer Prevention.This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
Acknowledgements
Footnote
References
  • 1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009; 59(4) : 225 -49 [DOI][PubMed]
  • 2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010; 60(5) : 277 -300 [DOI][PubMed]
  • 3. Hewitson P, Glasziou P, Watson E, Towler B, Irwig L. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol. 2008; 103(6) : 1541 -9 [DOI][PubMed]
  • 4. Schoen RE, Pinsky PF, Weissfeld JL, Yokochi LA, Church T, Laiyemo AO, et al. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med. 2012; 366(25) : 2345 -57 [DOI][PubMed]
  • 5. Zauber AG, Winawer SJ, O'Brien MJ, Lansdorp-Vogelaar I, van Ballegooijen M, Hankey BF, et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med. 2012; 366(8) : 687 -96 [DOI][PubMed]
  • 6. Srivastava K, Srivastava A. Comprehensive review of genetic association studies and meta-analyses on miRNA polymorphisms and cancer risk. PLoS One. 2012; 7(11)[DOI][PubMed]
  • 7. Tokarz P, Blasiak J. The role of microRNA in metastatic colorectal cancer and its significance in cancer prognosis and treatment. Acta Biochim Pol. 2012; 59(4) : 467 -74 [PubMed]
  • 8. Bhardwaj A, Singh S, Singh AP. MicroRNA-based Cancer Therapeutics: Big Hope from Small RNAs. Mol Cell Pharmacol. 2010; 2(5) : 213 -9 [DOI][PubMed]
  • 9. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009; 136(2) : 215 -33 [DOI][PubMed]
  • 10. Visone R, Croce CM. MiRNAs and cancer. Am J Pathol. 2009; 174(4) : 1131 -8 [DOI][PubMed]
  • 11. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008; 105(30) : 10513 -8 [DOI][PubMed]
  • 12. Hui AB, Shi W, Boutros PC, Miller N, Pintilie M, Fyles T, et al. Robust global micro-RNA profiling with formalin-fixed paraffin-embedded breast cancer tissues. Lab Invest. 2009; 89(5) : 597 -606 [DOI][PubMed]
  • 13. Chim SS, Shing TK, Hung EC, Leung TY, Lau TK, Chiu RW, et al. Detection and characterization of placental microRNAs in maternal plasma. Clin Chem. 2008; 54(3) : 482 -90 [DOI][PubMed]
  • 14. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol. 2008; 141(5) : 672 -5 [DOI][PubMed]
  • 15. Wong TS, Liu XB, Wong BY, Ng RW, Yuen AP, Wei WI. Mature miR-184 as Potential Oncogenic microRNA of Squamous Cell Carcinoma of Tongue. Clin Cancer Res. 2008; 14(9) : 2588 -92 [DOI][PubMed]
  • 16. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007; 9(6) : 654 -9 [DOI][PubMed]
  • 17. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006; 6(11) : 857 -66 [DOI][PubMed]
  • 18. Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE, et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med. 2005; 353(17) : 1793 -801 [DOI][PubMed]
  • 19. Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA. 2008; 299(4) : 425 -36 [DOI][PubMed]
  • 20. Xi Y, Formentini A, Chien M, Weir DB, Russo JJ, Ju J, et al. Prognostic Values of microRNAs in Colorectal Cancer. Biomark Insights. 2006; 2 : 113 -21 [PubMed]
  • 21. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature. 2005; 435(7043) : 834 -8 [DOI][PubMed]
  • 22. Liang Z, Wu H, Xia J, Li Y, Zhang Y, Huang K, et al. Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem Pharmacol. 2010; 79(6) : 817 -24 [DOI][PubMed]
  • 23. Wang S, Lu S, Geng S, Ma S, Liang Z, Jiao B. Expression and clinical significance of microRNA-326 in human glioma miR-326 expression in glioma. Med Oncol. 2013; 30(1) : 373 [DOI][PubMed]
  • 24. Valencia K, Martin-Fernandez M, Zandueta C, Ormazabal C, Martinez-Canarias S, Bandres E, et al. miR-326 associates with biochemical markers of bone turnover in lung cancer bone metastasis. Bone. 2013; 52(1) : 532 -9 [DOI][PubMed]
  • 25. Epis MR, Giles KM, Barker A, Kendrick TS, Leedman PJ. miR-331-3p regulates ERBB-2 expression and androgen receptor signaling in prostate cancer. J Biol Chem. 2009; 284(37) : 24696 -704 [DOI][PubMed]
  • 26. Vernimmen D, Gueders M, Pisvin S, Delvenne P, Winkler R. Different mechanisms are implicated in ERBB2 gene overexpression in breast and in other cancers. Br J Cancer. 2003; 89(5) : 899 -906 [DOI][PubMed]
  • 27. Epis MR, Giles KM, Candy PA, Webster RJ, Leedman PJ. miR-331-3p regulates expression of neuropilin-2 in glioblastoma. J Neurooncol. 2014; 116(1) : 67 -75 [DOI][PubMed]
  • 28. Liu XH, Sun M, Nie FQ, Ge YB, Zhang EB, Yin DD, et al. Lnc RNA HOTAIR functions as a competing endogenous RNA to regulate HER2 expression by sponging miR-331-3p in gastric cancer. Mol Cancer. 2014; 13 : 92 [DOI][PubMed]
  • 29. Shen WW, Zeng Z, Zhu WX, Fu GH. MiR-142-3p functions as a tumor suppressor by targeting CD133, ABCG2, and Lgr5 in colon cancer cells. J Mol Med (Berl). 2013; 91(8) : 989 -1000 [DOI][PubMed]
  • 30. Zhou JL, Jiang Z, Wang ZW, Zou ST, Zhang YX, Cai W, et al. MicroRNA-142-3p is frequently upregulated in colorectal cancer and may be involved in the regulation of cell proliferation. Chin Sci Bull. 2013; 58(23) : 2836 -45 [DOI]
  • 31. Zaytseva YY, Rychahou PG, Gulhati P, Elliott VA, Mustain WC, O'Connor K, et al. Inhibition of fatty acid synthase attenuates CD44-associated signaling and reduces metastasis in colorectal cancer. Cancer Res. 2012; 72(6) : 1504 -17 [DOI][PubMed]
  • 32. Sander S, Bullinger L, Klapproth K, Fiedler K, Kestler HA, Barth TF, et al. MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. Blood. 2008; 112(10) : 4202 -12 [DOI][PubMed]
  • 33. Lu J, He ML, Wang L, Chen Y, Liu X, Dong Q, et al. MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2. Cancer Res. 2011; 71(1) : 225 -33 [DOI][PubMed]
  • 34. Reuland SN, Smith SM, Bemis LT, Goldstein NB, Almeida AR, Partyka KA, et al. MicroRNA-26a is strongly downregulated in melanoma and induces cell death through repression of silencer of death domains (SODD). J Invest Dermatol. 2013; 133(5) : 1286 -93 [DOI][PubMed]
  • 35. Dang X, Ma A, Yang L, Hu H, Zhu B, Shang D, et al. MicroRNA-26a regulates tumorigenic properties of EZH2 in human lung carcinoma cells. Cancer Genet. 2012; 205(3) : 113 -23 [DOI][PubMed]
  • 36. Zhang B, Liu XX, He JR, Zhou CX, Guo M, He M, et al. Pathologically decreased miR-26a antagonizes apoptosis and facilitates carcinogenesis by targeting MTDH and EZH2 in breast cancer. Carcinogenesis. 2011; 32(1) : 2 -9 [DOI][PubMed]
  • 37. Jinushi T, Shibayama Y, Kinoshita I, Oizumi S, Jinushi M, Aota T, et al. Low expression levels of microRNA-124-5p correlated with poor prognosis in colorectal cancer via targeting of SMC4. Cancer Med. 2014; 3(6) : 1544 -52 [DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments